DOCSLIB.ORG

Machine Perfusion in Kidney Transplantation

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Machine Perfusion in Kidney Transplantation MACHINE PERFUSION IN KIDNEY TRANSPLANTATION: CLINICAL APPLICATION & METABOLOMIC ANALYSIS By ALISON J GUY (MBChB, FRCS) A thesis submitted to the University of Birmingham for the degree of DOCTOR OF MEDICINE Department of Immunity and Infection University of Birmingham & Department of Renal Surgery University Hospitals Birmingham 30th March 2015 University of Birmingham Research Archive e-theses repository This unpublished thesis/dissertation is copyright of the author and/or third parties. The intellectual property rights of the author or third parties in respect of this work are as defined by The Copyright Designs and Patents Act 1988 or as modified by any successor legislation. Any use made of information contained in this thesis/dissertation must be in accordance with that legislation and must be properly acknowledged. Further distribution or reproduction in any format is prohibited without the permission of the copyright holder. ABSTRACT Kidney Transplantation is the gold standard treatment for patients with end-stage renal failure. Most kidneys used for transplantation are from deceased donors and ensuring successful outcomes depends on many factors. One of these is organ storage. Hypothermic Machine Perfusion (HMP) of deceased donor organs has been shown to have several benefits. However, it has not been widely adopted and the underlying mechanism is poorly understood. The first section of this thesis examines the introduction of HMP into clinical practice. HMP outcomes were similar to those of standard storage techniques but with the additional benefit of increasing safe storage times. This was likely due to inherent benefits of the machine itself, improved recipient preparation and better peri- operative conditions. The second part of this study analysed HMP perfusate using metabolomics (Nuclear Magnetic Resonance) to identify potential predictors of graft outcome. Differences were identified in the metabolic profiles of perfusate from kidneys with immediate and delayed graft function. These may have a future role in viability assessment. Improved understanding of metabolism during storage may help target optimization strategies for deceased donor organs. 2 The final part of this study describes the development of a porcine model of transplantation to test future hypotheses. 3 ACKNOWLEDGEMENTS This work would not have been possible without the help and support of a number of people. I would first like to thank my supervisors Andrew Ready and Mark Cobbold for their invaluable guidance with this project. Also, other members of the renal research team who were a source of ideas and practical help – Nicholas Inston, Mel Field, Jay Nath and Damian McGrogan. The metabolomics work would not have been possible without the help, and patience, of Christian Ludwig and Daniel Tennant. Assistance with histology preparation and analysis was provided by Desley Neal and the UHB histology lab. I would also like to thank Peter DeMuylder and Gunther Vanwezer from Organ Recovery Systems who provided essential funding and shared their expertise in organ perfusion. Assistance with statistical analysis was provided by the UHB statistics department, mainly James Hodson, to whom I am very grateful. I would like to thank all of the clinical renal transplant team for co-operating with this research and providing their opinions and advice, along with Buta Basi who assisted with many practical arrangements. In addition, thanks to the staff at FA Gill Ltd who must have found my requests and arrangements for the perfusion of pig kidneys slightly unusual. 4 LIST OF CONTENTS CHAPTER ONE: INTRODUCTION 22 1.1 Chronic Kidney Disease (CKD) 23 1.1.1 CKD - Definitions & Staging 23 1.1.2 CKD - Prevalence, Incidence & Economic Burden 25 1.1.3 CKD - Aetiology/Pathology 30 1.1.4 CKD - Disease Progression 32 1.1.5 CKD - Management 33 1.2 Renal Transplantation (RT) 35 1.2.1 RT - Overview / Definitions 35 1.2.2 RT - Cold Ischaemic Time 37 1.2.3 RT - Outcomes 37 1.2.4 RT - The Organ Shortage & Marginal Organs 39 1.2.5 RT - Ischaemia-Reperfusion Injury 41 1.3 Organ Preservation 46 1.3.1 History of Organ Preservation 46 1.3.2 Preservation Fluids 48 1.3.3 Static Cold Storage 54 1.3.4 Hypothermic Machine Perfusion 55 1.3.5 HMP Mechanisms 60 1.3.6 HMP Viability Assessment 61 1.3.7 HMP Pharmacological Manipulation 64 1.3.8 HMP Clinical Outcomes 65 5 1.3.9 Other Preservation Methods 69 1.4 Overall Aims 74 CHAPTER TWO: ASSESSMENT OF CLINICAL UTILITY 76 2.1 Background 77 2.1.1 Aims 79 2.1.2 Setting 79 2.2 Methods 81 2.2.1 Patient Recruitment 81 2.2.2 Kidney Preservation 81 2.2.3 Data Collection & Outcome Measures 82 2.2.4 Statistical Analysis 83 2.3 Results 84 2.3.1 Donor & Recipient Demographics 84 2.3.2 Delayed Graft Function (DGF) 86 2.3.3 Cold Ischaemic Time and Timing of Surgery 87 2.3.4 HMP Parameters 90 2.3.5 Complications & Length of Stay 93 2.3.6 Post-Operative Creatinine 94 2.3.7 Histology 95 2.4 Discussion 97 2.4.1 Donor & Recipient Considerations 97 2.4.2 Use Of HMP & CIT 98 2.4.3 Resistance 100 6 2.4.4 Post-Operative Creatinine 101 2.4.5 Biopsy-Proven Acute Rejection Rates 101 2.4.6 Limitations 101 2.4.7 Conclusion 103 CHAPTER THREE: ANALYSIS OF HMP PERFUSATE 105 3.1 Background 106 3.1.1 Metabolomics 107 3.1.2 Metabolomic Investigations 110 3.1.3 Principles of Nuclear Magnetic Resonance (NMR) 111 3.1.4 NMR in Disease Studies 112 3.1.5 NMR in Transplantation 112 3.1.6 Key Metabolic Pathways 114 3.1.6.1 Glycolysis 115 3.1.6.2 The Citric Acid Cycle 117 3.1.6.3 Oxidative Phosphorylation 118 3.1.6.4 The Pentose Phosphate Pathway 119 3.1.6.5 The Urea Cycle 120 3.1.6.6 Fatty Acid Beta-Oxidation 121 3.1.6.7 Gluconeogenesis 122 3.2 Aims 125 3.3 Methods 125 3.3.1 Ethics & Sponsorship 125 3.3.2 Patient Recruitment 125 7 3.3.3 Kidney Preservation 126 3.3.4 Sample Collection 126 3.3.5 Sample Processing 127 3.3.6 Spectral Acquisition 127 3.3.7 Spectral Analysis 128 3.3.8 Statistical Analysis 133 3.4 Results 134 3.4.1 Identified Metabolites 136 3.4.2 Metabolites in KPS-1® 137 3.4.3 New Metabolites in Perfusate 138 3.4.4 Graft Function & Metabolomic Profile 140 3.4.4.1 Glucose 140 3.4.4.1.1 Correlation of Glucose Measurements 141 3.4.4.2 Inosine 143 3.4.4.3 Leucine 143 3.4.4.4 Gluconate 144 3.4.4.5 Other Metabolites 145 3.4.5 ROCS for Prediction of Delayed Graft Function 150 3.5 Discussion 152 3.5.1 Constituents of KPS-1® 154 3.5.1.1 Adenine & Ribose 155 3.5.1.2 Gluconate & Mannitol 156 3.5.1.3 Glutathione 156 3.5.1.4 Glucose 157 8 3.5.2 New Metabolites in Perfusate 158 3.5.2.1 Leucine 158 3.5.2.2 Inosine 159 3.5.2.3 Other Metabolites 159 3.5.3 Prediction of Delayed Graft Function 160 3.5.4 Limitations 161 3.5.5 Conclusion 162 CHAPTER FOUR: DEVELOPMENT & ASSESSMENT OF A PORCINE MODEL 163 4.1 Background 164 4.2 Aims 165 4.3 Methods 166 4.3.1 Sourcing of Porcine Kidneys 166 4.3.2 Porcine Kidney Recovery 166 4.3.3 Porcine Kidney Flush 166 4.3.4 HMP Technique 167 4.3.5 Sample Collection 167 4.3.6 Modifications 168 4.3.7 Preparation for NMR 170 4.3.7.1 Sample Processing 170 4.3.7.2 Spectral Acquisition 171 4.3.7.3 Spectral Analysis 171 4.3.7.4 Statistical Analysis of Porcine Data 173 4.3.8 Histological Preparation for Light Microscopy 174 9 4.3.9 Histological Preparation for Electron Microscopy 174 4.3.10 Comparison of Porcine & Human HMP Kidneys 179 4.3.11 Statistical Analysis of Porcine & Human Kidneys 180 4.4 Results 181 4.4.1 Ischaemic Times 181 4.4.2 Porcine HMP Parameters 181 4.4.3 Porcine NMR Analysis 184 4.4.4 Porcine Histology 190 4.4.4.1 Light Microscopy 190 4.4.4.2 Electron Microscopy 190 4.4.4.2.1 Endothelial Cells 190 4.4.4.2.2 Epithelial Cells 192 4.4.4.2.3 Glomerular Basement Membrane/Endothelium 194 4.4.4.2.4 Arteriolar Smooth Muscle 196 4.4.4.2.5 Tubules 198 4.4.4.2.6 Peritubular Capillaries 200 4.4.5 Comparison of Porcine and Human HMP Kidneys 202 4.4.5.1 Ischaemic Times 202 4.4.5.2 HMP Parameters 202 4.4.5.3 Metabolomics 204 4.5 Discussion 209 4.5.1 The Porcine Model 209 4.5.2 Porcine Ischaemic Times 211 4.5.3 Porcine HMP Parameters 211 10 4.5.4 Porcine NMR Analysis 211 4.5.5 Porcine Histology 214 4.5.6 Comparison of Porcine & Human HMP Kidneys 215 4.5.7 Limitations 218 4.5.8 Conclusions 219 CHAPTER 5: CONCLUDING REMARKS 221 CHAPTER 6: REFERENCES 228 CHAPTER 7: APPENDICES 263 7.1 Research Protocol 264 7.2 Ethics Favourable Opinion Letter 287 7.3 Cut-Off Values for ROC Curves 291 7.4 Metabolite Concentrations Measured in Kidney Perfusate of 292 SCS & HMP Porcine Kidneys (All Metabolites) 7.5 Box and Whisker Plot to Represent Concentrations of Metabolites 294 in HMP & SCS Porcine Kidney Perfusate (Non-Significant Metabolites) CHAPTER 8: PUBLICATIONS AND PRESENTATIONS 296 Declaration 299 Transplantation article 300 11 LIST OF TABLES Table 1.1: Staging System for CKD – National Kidney Foundation Table 1.2: Revised Staging System for CKD - KDIGO Table 1.3: Grading System for Albuminuria – KDIGO Table 1.4: Classification of Causes of CKD Based on Presence or Absence of Systemic Disease and Location Within the Kidney of Pathological- Anatomical Findings Table 1.5: Percentage Distribution of Primary Renal Diagnosis by Age (2012) Table 1.6: Constituents of KPS-1® Table 1.7: Proposed Advantages and Disadvantages of Normothermic Preservation Table 2.1: Donor and recipient demographics Table 2.2: Delayed Graft Function by Donor Type and Storage Group Table 2.3: In-patient Complications Following Deceased Donor Renal Transplantation Table 2.4: Histology of Post-transplant Kidney Biopsies Table 3.1: Chemical Shifts References Used for Metabolite Quantification Table
Load more

Recommended publications
  • Hypothermic Oxygenated Perfusion Versus Static Cold Storage For
    JMIR RESEARCH PROTOCOLS Ravaioli et al Protocol Hypothermic Oxygenated Perfusion Versus Static Cold Storage for Expanded Criteria Donors in Liver and Kidney Transplantation: Protocol for a Single-Center Randomized Controlled Trial Matteo Ravaioli1, MD, PhD, Prof Dr; Lorenzo Maroni1, MD; Andrea Angeletti2, MD; Guido Fallani1, MD; Vanessa De Pace1, MS; Giuliana Germinario1, MS; Federica Odaldi1, MD; Valeria Corradetti2, MD; Paolo Caraceni1, MD, Prof Dr; Maurizio Baldassarre1, MS, PhD; Francesco Vasuri3, MD, PhD; Antonia D©Errico3, MD, Prof Dr; Gabriela Sangiorgi4, MD; Antonio Siniscalchi1, MD; Maria Cristina Morelli1, MD; Anna Rossetto1, MD; Vito Marco Ranieri1, Prof Dr; Matteo Cescon1, MD, PhD, Prof Dr; Massimo Del Gaudio1, MD, PhD; Chiara Zanfi1, MD; Valentina Bertuzzo1, MD, PhD; Giorgia Comai2, MD, PhD; Gaetano La Manna2, MD, PhD, Prof Dr 1Department of Medical and Surgical Sciences, University of Bologna Sant©Orsola-Malpighi Hospital, Bologna, Italy 2Department of Experimental Diagnostic and Specialty Medicine, University of Bologna Sant©Orsola-Malpighi Hospital, Bologna, Italy 3Pathology Division, University of Bologna Sant©Orsola-Malpighi Hospital, Bologna, Italy 4Emilia-Romagna Transplantation Referral Center, Emilia-Romagna, Italy Corresponding Author: Matteo Ravaioli, MD, PhD, Prof Dr Department of Medical and Surgical Sciences University of Bologna Sant©Orsola-Malpighi Hospital Via Massarenti, 9 Bologna, 40138 Italy Phone: 39 051 2144810 Email: [email protected] Abstract Background: Extended criteria donors (ECD) are widely utilized due to organ shortage, but they may increase the risk of graft dysfunction and poorer outcomes. Hypothermic oxygenated perfusion (HOPE) is a recent organ preservation strategy for marginal kidney and liver grafts, allowing a redirect from anaerobic metabolism to aerobic metabolism under hypothermic conditions and protecting grafts from oxidative species±related damage.
    [Show full text]
  • Ischemia-Reperfusion Injuries Assessment During Pancreas Preservation
    International Journal of Molecular Sciences Review Ischemia-Reperfusion Injuries Assessment during Pancreas Preservation Thomas Prudhomme 1,2 , John F. Mulvey 3 , Liam A. J. Young 3,4 , Benoit Mesnard 1,2 , Maria Letizia Lo Faro 3, Ann Etohan Ogbemudia 3, Fungai Dengu 3, Peter J. Friend 3, Rutger Ploeg 3, James P. Hunter 3 and Julien Branchereau 1,2,3,* 1 Institut de Transplantation Urologie Néphrologie (ITUN), CHU Nantes, 44000 Nantes, France; [email protected] (T.P.); [email protected] (B.M.) 2 Centre de Recherche en Transplantation et Immunologie (CRTI) UMR1064, INSERM, Université de Nantes, 44000 Nantes, France 3 Nuffield Department of Surgical Sciences, University of Oxford, Oxford OX3 9DU, UK; [email protected] (J.F.M.); [email protected] (L.A.J.Y.); [email protected] (M.L.L.F.); [email protected] (A.E.O.); [email protected] (F.D.); [email protected] (P.J.F.); [email protected] (R.P.); [email protected] (J.P.H.) 4 Oxford Centre for Clinical Magnetic Resonance Research (OCMR), Radcliffe Department of Medicine, University of Oxford, Oxford OX3 9DU, UK * Correspondence: [email protected] Abstract: Maintaining organ viability between donation and transplantation is of critical importance for optimal graft function and survival. To date in pancreas transplantation, static cold storage (SCS) Citation: Prudhomme, T.; Mulvey, is the most widely practiced method of organ preservation. The first experiments in ex vivo perfusion J.F.; Young, L.A.J.; Mesnard, B.; Lo of the pancreas were performed at the beginning of the 20th century.
    [Show full text]
  • Utilizing Animal Studies to Evaluate Organ Preservation Devices ______Guidance for Industry and Food and Drug Administration Staff
    Contains Nonbinding Recommendations Utilizing Animal Studies to Evaluate Organ Preservation Devices ______________________________________________________________________________ Guidance for Industry and Food and Drug Administration Staff Document issued on May 8, 2019. The draft of this document was issued on September 15, 2017. For questions about this document, contact DHT3A: Division of Renal, Gastrointestinal, Obesity, and Transplant Devices at 301-796-7030. U.S. Department of Health and Human Services Food and Drug Administration Center for Devices and Radiological Health Contains Nonbinding Recommendations Preface Public Comment You may submit electronic comments and suggestions at any time for Agency consideration to https://www.regulations.gov. Submit written comments to the Dockets Management Staff, Food and Drug Administration, 5630 Fishers Lane, Room 1061, (HFA-305), Rockville, MD 20852. Identify all comments with the docket number FDA-2017-D-4886. Comments may not be acted upon by the Agency until the document is next revised or updated. Additional Copies Additional copies are available from the Internet. You may also send an e-mail request to [email protected] to receive a copy of the guidance. Please use the document number 1500083 to identify the guidance you are requesting. Contains Nonbinding Recommendations Table of Contents I. Introduction ........................................................................................................................... 1 II. Scope ....................................................................................................................................
    [Show full text]
  • Mitochondrial Targeting Therapy Role in Liver Transplant Preservation Lines: Mechanism and Therapeutic Strategies
    Open Access Review Article DOI: 10.7759/cureus.16599 Mitochondrial Targeting Therapy Role in Liver Transplant Preservation Lines: Mechanism and Therapeutic Strategies Anjli Tara 1, 2 , Jerry Lorren Dominic 3, 4, 5, 1 , Jaimin N. Patel 6 , Ishan Garg 7 , Jimin Yeon 7 , Marrium S. Memon 8 , Sanjay Rao Gergal Gopalkrishna Rao 9 , Seif Bugazia 10 , Tamil Poonkuil Mozhi Dhandapani 11, 12 , Amudhan Kannan 13, 14 , Ketan Kantamaneni 15, 16 , Myat Win 17, 1 , Terry R. Went 15 , Vijaya Lakshmi Yanamala 15 , Jihan A. Mostafa 18 1. General Surgery, California Institute of Behavioral Neurosciences & Psychology (CIBNP), Fairfield, USA 2. General Surgery, Liaquat University of Medical and Health Sciences (LUMHS), Jamshoro, PAK 3. General Surgery, Vinayaka Mission's Kirupananda Variyar Medical College, Salem, IND 4. General Surgery, Stony Brook Southampton Hospital, New York, USA 5. General Surgery and Orthopaedic Surgery, Cornerstone Regional Hospital, Edinburg, USA 6. Family Medicine, California Institute of Behavioral Neurosciences & Psychology (CIBNP), Fairfield, USA 7. Medicine, California Institute of Behavioral Neurosciences & Psychology (CIBNP), Fairfield, USA 8. Research, California Institute of Behavioral Neurosciences & Psychology (CIBNP), Fairfield, USA 9. Internal Medicine, California Institute of Behavioral Neurosciences & Psychology (CIBNP), Fairfield, USA 10. Faculty of Medicine, California Institute of Behavioral Neurosciences & Psychology (CIBNP), Fairfield, USA 11. Internal Medicine/Family Medicine, California Institute of Behavioral Neuroscience & Pyshology (CIBNP), Fairfield, USA 12. Internal Medicine, Medical City Plano, Plano, USA 13. Medicine, Jawaharlal Institute of Postgraduate Medical Education and Research (JIPMER), Puducherry, IND 14. General Surgery Research, California Institute of Behavioral Neurosciences & Psychology (CIBNP), Fairfield, USA 15. Surgery, California Institute of Behavioral Neurosciences & Psychology (CIBNP), Fairfield, USA 16.
    [Show full text]
  • Machine Perfusion of Donor Livers for Transplantation: a Proposal for Standardized Nomenclature and Reporting Guidelines
    Machine Perfusion of Donor Livers for Transplantation: A Proposal for Standardized Nomenclature and Reporting Guidelines The Harvard community has made this article openly available. Please share how this access benefits you. Your story matters Citation Karangwa, S. A., P. Dutkowski, P. Fontes, P. J. Friend, J. V. Guarrera, J. F. Markmann, H. Mergental, et al. 2016. “Machine Perfusion of Donor Livers for Transplantation: A Proposal for Standardized Nomenclature and Reporting Guidelines.” American Journal of Transplantation 16 (10): 2932-2942. doi:10.1111/ajt.13843. http:// dx.doi.org/10.1111/ajt.13843. Published Version doi:10.1111/ajt.13843 Citable link http://nrs.harvard.edu/urn-3:HUL.InstRepos:29738961 Terms of Use This article was downloaded from Harvard University’s DASH repository, and is made available under the terms and conditions applicable to Other Posted Material, as set forth at http:// nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of- use#LAA American Journal of Transplantation 2016; 16: 2932–2942 © 2016 The Authors. American Journal of Transplantation published by Wiley Periodicals Inc. Wiley Periodicals, Inc. on behalf of American Society of Transplant Surgeons doi: 10.1111/ajt.13843 Machine Perfusion of Donor Livers for Transplantation: A Proposal for Standardized Nomenclature and Reporting Guidelines S. A. Karangwa1,2, P. Dutkowski3, P. Fontes4,5, With increasing demand for donor organs for trans- P. J. Friend6, J. V. Guarrera7, J. F. Markmann8, plantation, machine perfusion (MP) promises to be a beneficial alternative preservation method for donor H. Mergental9, T. Minor10, C. Quintini11, 12 13 14 livers, particularly those considered to be of subopti- M.
    [Show full text]
  • Design, Analysis, and Pitfalls of Clinical Trials Using Ex Situ Liver Machine Perfusion: the International Liver Transplantation Society Consensus Guidelines
    Henry Ford Health System Henry Ford Health System Scholarly Commons Surgery Articles Surgery 4-1-2021 Design, Analysis, and Pitfalls of Clinical Trials Using Ex Situ Liver Machine Perfusion: The International Liver Transplantation Society Consensus Guidelines Paulo N. Martins Michael D. Rizzari Davide Ghinolfi Ina Jochmans Magdy Attia See next page for additional authors Follow this and additional works at: https://scholarlycommons.henryford.com/surgery_articles Authors Paulo N. Martins, Michael D. Rizzari, Davide Ghinolfi, Ina Jochmans, Magdy Attia, Rajiv Jalan, and Peter J. Friend Original Clinical Science—Liver Design, Analysis, and Pitfalls of Clinical Trials Using Ex Situ Liver Machine Perfusion: The International Liver Transplantation Society Consensus Guidelines Paulo N. Martins, MD, PhD,1 Michael D. Rizzari, MD,2 Davide Ghinolfi, MD, PhD,3 Ina Jochmans, MD, PhD,4,5 Magdy Attia, MD,6 Rajiv Jalan, MD, PhD,7 and Peter J. Friend, MD8 Background. Recent trials in liver machine perfusion (MP) have revealed unique challenges beyond those seen in most clinical studies. Correct trial design and interpretation of data are essential to avoid drawing conclusions that may com- promise patient safety and increase costs. Methods. The International Liver Transplantation Society, through the Special Interest Group “DCD, Preservation and Machine Perfusion,” established a working group to write consensus statements and guidelines on how future clinical trials in liver perfusion should be designed, with particular focus on relevant clinical endpoints and how different techniques of liver perfusion should be compared. Protocols, abstracts, and full published papers of clinical trials using liver MP were reviewed. The use of a simplified Grading of Recommendations Assessment, Development, and Evaluation working group (GRADE) system was attempted to assess the level of evidence.
    [Show full text]
  • BTS: UK Guidelines on Pancreas and Islet Transplantation
    The Voice of Transplantation in the UK UK Guidelines on Pancreas and Islet Transplantation September 2019 Compiled by a Working Party of The British Transplantation Society NHS Evidence accredited provider NHS Evidence - provider by NICE www.evidence.nhs.uk British Transplantation Society Guidelines © British Transplantation Society www.bts.org.uk CONTENTS 1 Introduction...........................................................................................................4 1.1 The Need for Guidelines………………………………………………………..4 1.2 Process of Writing and Methodology………………………………….………5 1.3 Contributing Authors…................................................................................5 1.4 Declarations of Interest……………………………………………………...….7 1.5 Grading of Recommendations…………………………………………...…….8 1.6 Abbreviations…………………………...………………………………...……..9 1.7 Definitions and Scope……………………………………………………...….10 1.8 Disclaimer……………………………………………………………...……….11 2 Executive Summary of Recommendations......................................................13 3 Ethics...................................................................................................................20 3.1 Definitions..................................................................................................20 3.2 Pancreas Transplantation: Introduction.....................................................21 3.3 Pancreas Transplantation: The Donor Perspective...................................23 3.4 Pancreas Transplantation: The Recipient Perspective.............................23
    [Show full text]
  • Hypothermic Machine Perfusion As an Alternative to Biopsy Assessment in Transplantation of Kidneys Donated After Cardiocirculatory Death: a Pilot Study
    Hypothermic Machine Perfusion as an Alternative to Biopsy Assessment in Transplantation of Kidneys Donated After Cardiocirculatory Death: A Pilot Study Massimiliano Bissolatia, Fioralba Pindozzia, Giovanni Guarneria, Olga Adamenkoa, Fabio Giannonea, Michele Mazzaa, Giulia Maggia, Riccardo Rosatib, Antonio Secchic, and Carlo Soccia,* aTransplant and Metabolic-Bariatric Surgery, San Raffaele Scientific Institute, Milan, Italy; bGastrointestinal Surgery, San Raffaele Scientific Institute, Milan, Italy; and cTransplant Medicine, San Raffaele Scientific Institute, Milan, Italy ABSTRACT Background. Transplantation of kidneys from donation after cardiocirculatory death (DCD) donors is becoming an ever-increasing reality. So far, biopsy histologic assessment is the main parameter for evaluation of graft suitability, but it has several drawbacks and has poor reliability. The aim of this study is to verify if real-time renal resistance (RR) measurement during hypothermic machine perfusion (HMP) can be used as a reliable parameter to evaluate the quality of grafts from DCD and extracorporeal membrane oxygenation (ECMO) donors. Methods. From January 2015 to September 2018, HMP has been systematically applied to all organs from DCD and ECMO donors. All grafts underwent preimplantation biopsy histologic assessment with Karpinski’s score. Single kidney transplants (SKTs) or double kidney transplants (DKTs) were performed according to biopsy score results. Kidneys were considered suitable for transplant if RR reached 1.0 within 3 hours of perfusion. RR trend and postoperative outcome were analyzed considering biopsy score and donor type. Results. A total of 30 kidneys (15 from DCD and 15 from ECMO donors) were used to perform 26 transplants (22 SKTs and 4 DKTs). Considering RR trend, all grafts were considered suitable for transplant within 1 hour of perfusion.
    [Show full text]
  • Hypothermic Machine Preservation of the Liver: State of the Art
    Current Transplantation Reports (2018) 5:93–102 https://doi.org/10.1007/s40472-018-0183-z MACHINE PRESERVATION OF THE LIVER (C MILLER AND C QUINTINI, SECTION EDITORS) Hypothermic Machine Preservation of the Liver: State of the Art Andrea Schlegel1,2 & Xavier Muller3 & Philipp Dutkowski3 Published online: 22 January 2018 # The Author(s) 2018. This article is an open access publication Abstract Purpose of Review In this review, we highlight which livers may benefit from additional treatment before implantation and describe the concept of hypothermic machine liver perfusion. Furthermore, we explain why cold oxygenated perfusion concepts could potentially lead to a breakthrough in this challenging field of transplantation. Accordingly, we summarize recent clinical applications of different hypothermic perfusion approaches. Recent Findings The impact of end-ischemic, hypothermic liver perfusion in liver transplantation is currently assessed by two multicenter, randomized controlled trials. Recently, new applications of hypothermic perfusion showed promising results and recipients were protected from severe intrahepatic biliary complications, despite the use of very extended criteria grafts including donation after circulatory death livers. Summary Hypothermic machine liver perfusion is beneficial for high-risk livers and protects recipients from most feared complications. Importantly, such easy approach is currently implemented in several European centers and new markers obtained from perfusate may improve the prediction of liver function in
    [Show full text]
  • Oxygen Transport During Ex Situ Machine Perfusion of Donor Livers Using Red Blood Cells Or Artificial Oxygen Carriers
    International Journal of Molecular Sciences Review Oxygen Transport during Ex Situ Machine Perfusion of Donor Livers Using Red Blood Cells or Artificial Oxygen Carriers Silke B. Bodewes 1,2 , Otto B. van Leeuwen 1,3, Adam M. Thorne 1,3, Bianca Lascaris 1,3, Rinse Ubbink 3, Ton Lisman 2 , Diethard Monbaliu 4,5 , Vincent E. De Meijer 1 , Maarten W. N. Nijsten 6 and Robert J. Porte 1,* 1 Section of Hepatobiliary Surgery and Liver Transplantation, Department of Surgery, University of Groningen, University Medical Center Groningen, 9713 GZ Groningen, The Netherlands; [email protected] (S.B.B.); [email protected] (O.B.v.L.); [email protected] (A.M.T.); [email protected] (B.L.); [email protected] (V.E.D.M.) 2 Surgical Research Laboratory, Department of Surgery, University of Groningen, University Medical Center Groningen, 9713 GZ Groningen, The Netherlands; [email protected] 3 Organ Preservation & Resuscitation Unit, University Medical Center Groningen, 9713 GZ Groningen, The Netherlands; [email protected] 4 Department of Abdominal Transplantation Surgery and Coordination, University Hospitals Leuven, 3000 Leuven, Belgium; [email protected] 5 Transplantation Research Group, Department of Microbiology, Immunology, and Transplantation, Katholieke Universiteit Leuven, 3000 Leuven, Belgium 6 Department of Critical Care, University of Groningen, University Medical Center Groningen, 9713 GZ Groningen, The Netherlands; [email protected] * Correspondence: [email protected]; Tel./Fax: +31-50-3611745 Abstract: Oxygenated ex situ machine perfusion of donor livers is an alternative for static cold preservation that can be performed at temperatures from 0 ◦C to 37 ◦C.
    [Show full text]
  • Mitochondrial Reprogramming—What Is the Benefit of Hypothermic
    Review Mitochondrial Reprogramming—What Is the Benefit of Hypothermic Oxygenated Perfusion in Liver Transplantation? Rebecca Panconesi 1,2, Mauricio Flores Carvalho 1, Matteo Mueller 3 , Philipp Dutkowski 3, Paolo Muiesan 1 and Andrea Schlegel 1,3,* 1 Hepatobiliary Unit, Careggi University Hospital, University of Florence, 50134 Florence, Italy; [email protected] (R.P.); [email protected] (M.F.C.); paolo.muiesan@unifi.it (P.M.) 2 General Surgery 2U-Liver Transplant Unit, Department of Surgery, A.O.U. Città della Salute e della Scienza di Torino, University of Turin, 10124 Turin, Italy 3 Swiss HPB and Transplant Center, Department of Visceral Surgery and Transplantation, University Hospital Zurich, 8091 Zurich, Switzerland; [email protected] (M.M.); [email protected] (P.D.) * Correspondence: [email protected] Abstract: Although machine perfusion is a hot topic today, we are just at the beginning of understand- ing the underlying mechanisms of protection. Recently, the first randomized controlled trial reported a significant reduction of ischemic cholangiopathies after transplantation of livers donated after circulatory death, provided the grafts were treated with an endischemic hypothermic oxygenated Citation: Panconesi, R.; Flores perfusion (HOPE). This approach has been known for more than fifty years, and was initially mainly Carvalho, M.; Mueller, M.; used to preserve kidneys before implantation. Today there is an increasing interest in this and other Dutkowski, P.; Muiesan, P.; Schlegel, dynamic preservation technologies and various centers have tested different approaches in clinical A. Mitochondrial trials and cohort studies. Based on this, there is a need for uniform perfusion settings (perfusion route Reprogramming—What Is the Benefit and duration), and the development of general guidelines regarding the duration of cold storage of Hypothermic Oxygenated in context of the overall donor risk is also required to better compare various trial results.
    [Show full text]
  • Publication Export
    Tuesday, October 2, 2018 2:30 PM - 4:00 PM Scholar Award Abstract Session OR1 INVISIBLE ORGANS MADE BY GENETIC ENGINEERING TO TURN OFF MHC PRIOR TO ALLOGENEIC TRANSPLANTATION PREVENT A PRO-INFLAMMATORY CYTOKINE RESPONSE IN THE RECIPIENT Constanca Figueiredo, Marco Carvalho Oliveira, Chen Chen-Wacker, Klaus Hoeffler, Mark Kuehnel, Katharina Jansson, Axel Haverich, Gregor Warnecke, Rainer Blasczyk, Hannover Medical School, Hannover, GERMANY. Aim: HLA and minor antigen mismatches are the main causes of allograft rejection and graft failure. We have shown in mice and rats that MHC silenced cells and tissues are protected against immune rejection. We also demonstrated in porcine lungs that SLA expression can be turned off in a complex vascularized organ. In this study we evaluated the effect of MHC I silencing prior to allogeneic lung transplantation (Tx) in an established porcine Tx model by monitoring the cytokine response during the first 12 weeks after Tx with immunosuppression given only in the first 4 weeks. Methods: SLA I was permanently silenced during normothermic ex vivo perfusion with lentiviral vectors encoding short hairpin RNAs targeting b2m (n=2). A lentivirally transduced non-specific shRNA was used in the control lung Tx group (n=3). NanoLuc was used as a reporter gene in both groups. In each transplant experiment both donor lungs were genetically engineered with one lung being transplanted and the other lung used for quality control. Levels of b2m mRNA and SLA were quantified by RT-PCR and flow cytometry. SLA downregulation of endothelial cells was advisedly designed to not exceed 70%. Cytokines were monitored every second day after Tx and weekly after the post-operative day (POD) 7 by multiplex technology.
    [Show full text]